Please ensure Javascript is enabled for purposes of website accessibility

EntreMed reports higher loss in 4Q

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported a fourth-quarter net loss of $1.3 million, or 5 cents per diluted share, versus a net loss of $360,000, or 2 cents per diluted share, for the prior-year period.

EntreMed attributed the higher net loss directly to declining royalties from Celgene Corp. on sales of Thalomid. Celgene, of Summit, N.J., licensed Thalomid, a drug used to treat cancer that is related to thalidomide, in 1996 from EntreMed.

The company reported no revenue in 2013’s fourth quarter versus $669,000 in revenue for the 2012 period.